Recent Updates
Recently added Catalysts
WGRX Positive Sentiment Score: 70/100

DataVault AI and Wellgistics Health Announce Plans for PharmacyChain to Implement Manufacturer-to-Patient Blockchain-enabled Smart Contracts for the Prescription Drug Industry to Improve Efficiency and Patient Outcomes S

Key Takeaway: DataVault AI and Wellgistics Health are collaborating to implement blockchain-enabled smart contracts in the prescription drug industry. This partnership aims to enhance efficiency, transparency, and patient outcomes within the $634 billion U.S. market. The initiative includes using AI for optimizing prescription services and ensuring compliance with healthcare standards. However, the partnership is contingent upon the successful negotiation of agreements, which poses a risk to the realization of its benefits.

Market Sentiment Analysis

POSITIVE FACTORS

  • The partnership aims to digitize the tracking of prescription drugs, improving efficiency.
  • Blockchain-enabled smart contracts are expected to enhance transparency and accountability.
  • Both companies anticipate creating measurable value for multiple stakeholders in the prescription ecosystem.

CONCERNS & RISKS

  • The collaboration is still in negotiation stages with no guarantee of final agreement or revenue generation.
  • Potential risks include the uncertainty of execution and the ability to maintain stock listings on Nasdaq.

Full Press Release Details

AI and Wellgistics Health Announce Plans for PharmacyChain to Implement Manufacturer-to-Patient Blockchain-enabled
Smart Contracts for the Prescription Drug Industry to Improve Efficiency and Patient Outcomes
Alliance Targets Digital Transformation of the $634.32 Billion (1) US Prescription Drug Market Through Blockchain-Enabled Data Monetization
and AI-Driven Efficiency Gains
OR, October 22, 2025 - DataVault AI, Inc. ("DataVault") (NASDAQ: DVLT), leading the way in AI data experience,
valuation, and monetization, and Wellgistics Health, Inc. ("Wellgistics") (NASDAQ: WGRX), a leader in next-generation
pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the two companies have entered
into a non-binding letter of intent to implement manufacturer-to-patient blockchain-enabled smart contracts ("PharmaChain ")
into Wellgistics proprietary Technology and Physical infrastructure for the prescription drug industry. The goal of the partnership will
be to seek to fully digitize tracking of prescription drugs from script to fulfillment in order to ensure the right drug gets to the
right patient at the right time, with the right recommendations for safe and effective use. The companies currently contemplate a revenue-sharing
arrangement from fees derived from the use of the PharmacyChain by pharmacies.
the past decade, DataVault AI has built a portfolio of patented technologies that position us at the forefront of data monetization and
blockchain innovation across multiple industries," said Nathaniel Bradley, CEO and Co founder of DataVault AI. "The $639
billion U.S. prescription drug market is entering a new era of digital transformation, and our PharmacyChain platform
represents a scalable opportunity to drive measurable value for every stakeholder-from manufacturers and physicians to pharmacies,
payers, and patients. By integrating blockchain-enabled smart contracts, we're creating a more efficient, transparent, and accountable
prescription ecosystem that aligns financial incentives with improved patient outcomes."
recently announced the introduction of HubRx AI, a fully customizable artificial intelligence agent (AI Agents) engine designed to streamline
the implementation of AI Agents for pharmacies. The AI Agents will help optimize prescription drug services, reduce pharmacist costs
and improve patient outcomes while adhering to strict healthcare privacy, security and compliance controls. HubRx is being integrated
with Wellgistics' other technology tools Einstein Rx AI clinical decision support and safety optimization and Wellgistics Hub (formerly
DelivMeds ) digital prescription routing infrastructure to pair with Wellgistics' physical infrastructure to help
meet patients where they are. Wellgistics physical infrastructure includes its distribution network (3PL and warehouse), trusted network
of over 6500 independent pharmacies nationwide and in-house pharmacy (physical and online).
patient access to prescription medicines by minimizing administrative burden through blockchain-enabled smart contracts is the next logical
step to help pharmacists ensure that patients get their medicines on time and on budget," said Prashant Patel, RPh, President &
Interim-CEO of Wellgistics. "Compliance with treatment regimens, improving patient safety by reducing drug-drug interactions due
to manual evaluation, eliminating waste, fraud & abuse and maximizing reimbursement for pharmacies while reducing administrative
burden for insurance companies are central pillars of what Wellgistics is bringing forward with PharmacyChain. By leveraging the key
enabling blockchain-based intellectual property developed by DataVault that covers our vertical, we are ensuring that we will have the
ability to conduct business over the long-term and build our ecosystem in a way that will allow us to increase our market share and margins
as we expand into new markets."
implementation of the PharmacyChain solution and any revenue-sharing arrangement will be subject to the negotiation and execution of
definitive agreements and the satisfaction of applicable conditions, and there can be no assurance that such agreements will be entered
into, that the contemplated collaboration will be consummated, or that any revenues will be generated.
AI (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web
3.0 environment. The company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic
Science and Data Science Divisions. Datavault AI's Acoustic Science Division features WiSA , ADIO
and Sumerian patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission
technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages
the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI's cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing
for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information
Data Exchange (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical
real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI's technology suite is completely
customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation
and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more about Datavault AI at www.dvlt.ai.
Wellgistics Health, Inc.
Health (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform
connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery,
and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic
alternative, Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.
more information, visit www.wellgisticshealth.com.
press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995, as amended, and other securities laws. Words such as "expect," "will," "anticipates," "continues"
and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. Such
forward-looking statements, including statements herein regarding our business opportunities and prospects, strategy, future revenue
expectations, licensing initiatives, patent initiatives as well as the successful implementation of the patented technologies, are necessarily
based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Readers are
cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: our
ability to successfully utilize all intellectual property that has been issued and granted Notices of Allowance; risks regarding our
ability to utilize the assets we acquire to successfully grow our market share; risks regarding our ability to open up new revenue streams
as a result of the various patents mentioned in this press release; our current liquidity position and the need to obtain additional
financing to support ongoing operations; general market, economic and other conditions; our ability to continue as a going concern; our
ability to maintain the listing of our common stock on Nasdaq; our ability to manage costs and execute on our operational and budget
plans; our ability to achieve our financial goals; the degree to which our licensees implement our technologies into their products,
if at all; the timeline to any such implementation; risks related to technology innovation and intellectual property, and other risks
as more fully described in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided
only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this
communication based on new information, future events, or otherwise, except as required by law.
press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical
facts. When Wellgistics Health uses words such as "may," "will," "intend," "should,"
"believe," "expect," "anticipate," "project," "estimate," or similar expressions
that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without
limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans.
Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results
to differ materially. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.
press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there
shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
Office: (646) 893-5835

Frequently Asked Questions

What is the goal of the PharmacyChain initiative?

PharmacyChain aims to digitize prescription drug tracking to ensure accuracy in drug delivery and recommendations.

Which companies are collaborating on PharmacyChain?

The initiative is a collaboration between DataVault AI and Wellgistics Health.

How does PharmacyChain enhance patient outcomes?

It improves efficiency and transparency in the prescription process, aligning incentives for better patient care.

What technology does PharmacyChain utilize?

PharmacyChain utilizes blockchain-enabled smart contracts for secure and efficient data management.

What is the financial focus of the PharmacyChain project?

The project includes a revenue-sharing model among pharmacies that utilize the PharmacyChain platform.

Last updated: Oct 22, 2025